

ASX ANNOUNCEMENT

5 February, 2025

Biome Secures FaBA Co-investment for IP Development

- Biome signs co-investment agreement with Australia's Food and Beverage Accelerator (FaBA) for a jointly funded IP development program
- Biome has executed an agreement with FaBA and its aligned universities, UQ, QUT and UniSQ to commence the partnership and work toward a joint project plan to develop Biome's BMB18 probiotic strain
- The agreement is supported by \$50M funding from the Australian Government Department of Education Trailblazer Program awarded to FaBA
- Any project budget will be matched by FaBA and its federal government research grant
- Biome will retain 100% ownership of the intellectual property related to *Lactobacillus plantarum* BMB18 and will retain intellectual property arising from the performance of the project, royalty free.

Microbiome health company **Biome Australia Limited** (ASX: BIO) ('Biome' or 'the company') is pleased to share the details of a new IP development partnership with the Australian Food and Beverage Accelerator (FaBA).

FaBA is a \$160 million initiative to foster collaboration between industry and university researchers. Its goal is to boost the growth and innovation of new food and beverage (F&B) ingredients and products that benefit Australia. FaBA provides the industry with access to research teams, industry professionals, state-of-the-art equipment and pilot facilities, hosted by The University of

For personal use only

Queensland (UQ) and in collaboration with the Queensland University of Technology (QUT), the University of Southern Queensland and UniQuest. Through its programs, FaBA aims to develop research capabilities, drive commercialisation and deliver value to the industry.

Biome is working with the team at FaBA and its university partners to work on the development of a joint research and development project on *Biome's Lactobacillus plantarum* BMB18 probiotic strain with the potential to expand the collaboration and funding support into other projects.

Biome recently shared with the market the results of the company's successful initial in vitro studies on BMB18, which highlighted the strain's functional potential and demonstrated an ability to effectively modulate immune responses and inflammation, reduce oxidative stress, and maintain intestinal barrier integrity. This new FaBA partnership is well timed to support *Biome* with the next stage of development of BMB18.

No financial contribution is due from *Biome* for the partnership, until the point of a project sign off. *Biome* maintains the authority to sign off on all projects and associated budgets, which will be matched by FaBA and its federal government research grant.

Biome will contribute up to \$550k under its discretion to the partnership over the next two years. This budget will only be used for *Biome* approved clinical research and will come with the benefit of matched funding.

As a core component of Vision 27, *Biome* has been working on a clinical development pipeline for BMB18. This partnership with FaBA may significantly reduce the cost of *Biome's* future financial investment in the research and development of this strain. *Biome* will retain 100% ownership of the intellectual property related to *Lactobacillus plantarum* BMB18 and will retain intellectual property arising from the performance of the project, royalty free.

This opportunity to access government financial support for the development of *Biome's* IP assets is an incredible opportunity for *Biome* and supports the

ongoing research and development and *Biome's* new product development pipeline.

Once *Biome* and FaBA agree on an initial project and sign off, *Biome* will be pleased to share the clinical development and downstream product targets for BMB18

-ENDS-

Approved for release by the Biome Australia board of directors.

About Biome Australia Limited

Biome Australia develops, licences, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics®.

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

For personal use only

Investor Relations

Jo Power

+61 (3) 9017 5800

corporate@biomeaustralia.com

Media enquiries

media@activated.co

Forward looking statements

*This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (**Forward Looking Statements**).*

Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance.

Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.